CERo Therapeutics Holdings Inc
CERO
Company Profile
Business description
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
Contact
201 Haskings Way
Suite 230
South San FranciscoCA94080
USAT: +1 650 407-2376
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
8
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,826.40 | 15.50 | -0.18% |
| CAC 40 | 7,723.47 | 27.20 | 0.35% |
| DAX 40 | 24,073.67 | 286.22 | 1.20% |
| Dow JONES (US) | 44,406.36 | 422.17 | -0.94% |
| FTSE 100 | 8,806.53 | 16.38 | -0.19% |
| HKSE | 23,887.83 | 28.23 | -0.12% |
| NASDAQ | 20,412.52 | 188.59 | -0.92% |
| Nikkei 225 | 39,587.68 | 223.20 | -0.56% |
| NZX 50 Index | 12,755.74 | 9.21 | -0.07% |
| S&P 500 | 6,229.98 | 49.37 | -0.79% |
| S&P/ASX 200 | 8,589.30 | 13.70 | -0.16% |
| SSE Composite Index | 3,473.13 | 0.81 | 0.02% |